Results 1 to 10 of about 56,747 (148)
Antibody–Drug Conjugates—A Tutorial Review [PDF]
Molecules, 2021 Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 ADCs currently in clinical development and eleven ADCs (nine containing small ...
Stephanie Baah +2 more
doaj +2 more sources
Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC. [PDF]
Antibodies (Basel)Wang K, Taing K, Hsu R.
europepmc +3 more sources
Pharmaceutics, 2023 Typically, antibody–drug conjugates (ADCs) are made up of a humanized antibody and a small-molecule medication connected by a chemical linker. ADCs’ ability to deliver cytotoxic agents to the specific site with reduced side effects showed promising ...
Lal Bahadur Pal +3 more
doaj +1 more source
Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed/Refractory Lymphomas
Hematology/Oncology and Stem Cell Therapy, 2023 Relapsed or refractory lymphoma is commonly treated with combination chemoimmunotherapy and cellular immunotherapy. Modest response rates and associated toxicities are obstacles to achieving durable remission using traditional cytotoxic chemotherapy ...
Hamza Hashmi +2 more
doaj +1 more source
Indian Journal of Medical and Paediatric Oncology, 2020 Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj +1 more source
Introduction to Antibody-Drug Conjugates
Antibodies, 2021 Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products in which a monoclonal antibody is linked to a small molecule drug with a stable linker.
Mark C. Pettinato
doaj +1 more source
Pharmaceuticals, 2022 Although there have been extensive research and progress on the discovery of anticancer drug over the years, the application of these drugs as stand-alone therapy has been limited by their off-target toxicities, poor pharmacokinetic properties, and low ...
Audrey Nathania Johan, Yi Li
doaj +1 more source
Antibody-drug conjugates for cancer therapy [PDF]
Farmacja Polska, 2021 Antibody – drug conjugates (ADCs) are drugs designed to target specific anti-cancer treatment. ADCs are immunoconjugates comprised of a monoclonal antibody attached to cytotoxic drug via a chemical linker.
Anna Grzywa
doaj +1 more source
Microbial Cell Factories, 2018 Pioneered exactly 20 years ago, yeast surface display (YSD) continues to take a major role in protein engineering among the high-throughput display methodologies that have been developed to date. The classical yeast display technology relies on tethering
Doreen Könning, Harald Kolmar
doaj +1 more source
Emerging new therapeutic antibody derivatives for cancer treatment
Signal Transduction and Targeted Therapy, 2022 Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells.
Shijie Jin +7 more
doaj +1 more source